Measures for promoting the rational use of medicines in the 27 EU Member States were surveyed in a report by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute).
Survey on rational use of medicines in 27 EU Members States
                
                    Home/Reports                
                |
                Posted 22/04/2011
                
                     0
                                            
                            Post your comment
0
                                            
                            Post your comment
                        
                                    
            
            Their results showed that there are many different practices between the different Member States in the EU with regard to generic medicine policies. An overview is given in the table below:
For example, while most countries (22) advocate international non-proprietary name (INN) prescribing, relatively few (4) have made this obligatory, whereas generic substitution by the pharmacist is practiced in the majority of countries (21).
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Related articles
The EU and rational use of medicines
The Netherlands and rational use of medicines
Italy’s rational use of medicines
France’s rational use of medicines
Germany’s rational use of medicines
Rational use of medicines in Denmark
Promoting rational use of medicines in Europe
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Canada poised to remove requirement for Phase III trials for biosimilars
European position paper on AI in medicinal product lifecycle
Policies & Legislation
US EO: delivering Most-Favored-Nation Prescription Drug Pricing to American patients
Uruguay to establish independent AUVISA drug agency for healthcare reform
China-to-West pharma licensing deals surge in 2024 amid innovation push
 
            
    
    
                                                                Home/Reports Posted 22/05/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets
 
            
    
    
                                                         
            
    
    
             
                             
                         
            
    
    
                                                                 
            
    
    
                                                                 
            
    
    
                                                                 
            
    
    
                                                         
            
    
    
                                                        
Post your comment